PDL BioPharma Current Ratio 2010-2020 | PDLI
PDL BioPharma current ratio from 2010 to 2020. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| PDL BioPharma Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2020-12-31 |
$0.00B |
|
0.00 |
| 2020-06-30 |
$0.50B |
$0.04B |
13.68 |
| 2020-03-31 |
$0.55B |
$0.04B |
13.21 |
| 2019-12-31 |
$0.31B |
$0.05B |
6.87 |
| 2019-09-30 |
$0.41B |
$0.04B |
9.94 |
| 2019-06-30 |
$0.40B |
$0.04B |
10.43 |
| 2019-03-31 |
$0.48B |
$0.04B |
11.02 |
| 2018-12-31 |
$0.52B |
$0.05B |
9.86 |
| 2018-09-30 |
$0.51B |
$0.05B |
10.88 |
| 2018-06-30 |
$0.51B |
$0.05B |
11.13 |
| 2018-03-31 |
$0.51B |
$0.05B |
10.03 |
| 2017-12-31 |
$0.64B |
$0.19B |
3.32 |
| 2017-09-30 |
$0.61B |
$0.19B |
3.16 |
| 2017-06-30 |
$0.54B |
$0.28B |
1.94 |
| 2017-03-31 |
$0.54B |
$0.28B |
1.98 |
| 2016-12-31 |
$0.40B |
$0.13B |
3.05 |
| 2016-09-30 |
$0.36B |
$0.12B |
2.92 |
| 2016-06-30 |
$0.32B |
$0.02B |
14.19 |
| 2016-03-31 |
$0.38B |
$0.03B |
13.04 |
| 2015-12-31 |
$0.28B |
$0.04B |
7.70 |
| 2015-09-30 |
$0.31B |
$0.10B |
3.24 |
| 2015-06-30 |
$0.37B |
$0.14B |
2.55 |
| 2015-03-31 |
$0.50B |
$0.34B |
1.46 |
| 2014-12-31 |
$0.36B |
$0.19B |
1.89 |
| 2014-09-30 |
$0.34B |
$0.26B |
1.31 |
| 2014-06-30 |
$0.23B |
$0.31B |
0.75 |
| 2014-03-31 |
$0.36B |
$0.35B |
1.03 |
| 2013-12-31 |
$0.11B |
$0.41B |
0.26 |
| 2013-09-30 |
$0.33B |
$0.21B |
1.59 |
| 2013-06-30 |
$0.28B |
$0.24B |
1.20 |
| 2013-03-31 |
$0.26B |
$0.07B |
3.76 |
| 2012-12-31 |
$0.18B |
$0.01B |
17.47 |
| 2012-09-30 |
$0.20B |
$0.03B |
6.28 |
| 2012-06-30 |
$0.24B |
$0.09B |
2.56 |
| 2012-03-31 |
$0.21B |
$0.15B |
1.38 |
| 2011-12-31 |
$0.23B |
$0.13B |
1.76 |
| 2011-09-30 |
$0.22B |
$0.17B |
1.26 |
| 2011-06-30 |
$0.21B |
$0.22B |
0.98 |
| 2011-03-31 |
$0.19B |
$0.35B |
0.53 |
| 2010-12-31 |
$0.29B |
$0.19B |
1.47 |
| 2010-09-30 |
$0.24B |
$0.21B |
1.13 |
| 2010-06-30 |
$0.24B |
$0.31B |
0.78 |
| 2010-03-31 |
$0.33B |
$0.42B |
0.80 |
| 2009-12-31 |
$0.32B |
$0.29B |
1.08 |
| 2009-09-30 |
$0.25B |
$0.27B |
0.94 |
| 2009-06-30 |
$0.21B |
$0.07B |
3.07 |
| 2009-03-31 |
$0.21B |
$0.13B |
1.61 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.000B |
$0.000B |
|
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
|
